中枢神经系统原发性弥漫大 B 细胞淋巴瘤中 PD-L1、CD4、CD8 和 PD-1 的相关性研究

We investigated the clinicopathological role of the PD-1/PD-L1 pathway in the primary diffuse large B-cell lymphoma of the central nervous system (PCNS-DLBCL). Standardized staining for PD-L1 was performed by machine staining, and internationally accepted interpretation methods were used. The PD-L1 immunostaining ≥ 20 % of all cells in slices was defined as high expression of PD-L1. CD4, CD8, and PD-1 tumor-infiltrating lymphocytes (TILs) were enumerated, and the median was defined as the cutoff value. Values higher than the median was defined as high expression. Thirty-four cases (64.

2 %) showed high expression of PD-L1. PD-L1 expression was associated with a good prognosis when 20 % was considered as cutoff value and had the smallest P value. By contrast, a low number of CD8 + or PD-1 + TILs was associated with poor prognosis. Patients with low expression of PD-L1 had poor overall survival (P = 0.

001), and those with increased CD8 or PD-1 TILs tended to have improved overall survival (P = 0. 004 and 0. 024, respectively). Low number of monocytes, increased number of lymphocytes, IPI score ≥ 2, ECOG PS ≥ 2, LDH ≥ 250, and Ki67 ≥ 70 % were independent prognostic factors for OS.

In conclusion, PD-L1 expression, CD8 and PD-1 TILs, monocyte status, and ECOG PS might be prognostic markers and therapeutic targets of PCNS-DLBCL.